This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of -4.76% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q1 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings
by Zacks Equity Research
Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%
by Zacks Equity Research
BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Can The Uptrend Continue for BeyondSpring (BYSI)?
by Zacks Equity Research
Investors certainly have to be happy with BeyondSpring Inc. (BYSI) and its short term performance.
BeyondSpring Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BeyondSpring has been struggling lately, but the selling pressure may be coming to an end soon.
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
Why BeyondSpring (BYSI) Could Be a Potential Winner
by Zacks Equity Research
Although overlooked by the investors, BeyondSpring (BYSI) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.